Biomaterials for a better life
The last mile of delivering a drug to a patient occurs in their own body - from the circulatory system to the intended organ.
Oligo Medic has developed a versatile, polysaccharide-based proprietary nanoparticle architecture with the potential to improve the benefits and reduce the risks for a wide class of therapeutic molecules.
Unlocking the full
potential of biomaterials
Learn more
Oligo Medic has developed a proprietary nanoparticle architecture combining stealth and active targeting with the potential to efficiently deliver a wide range of therapeutic payloads, drastically increasing the proportion of drug reaching the intended target.
The company is undertaking its own clinical program and open to partnerships for making its unique targeted delivery system available to bringing the most promising new drugs to market
Confirmatory Phase
Target
Encapsulated Drug
Solid Tumors
Selected anticancer drugs
Rights
Fully owned
Preclinical Phase
An alternative to HA injections with fundamentally longer residence time, designed specifically for effective and long-lasting lubrication of joints under abrasive stress.
A new and improved dermal injection for creating facial volume with the same satisfactory characteristics of HA, but fundamentally longer lasting outcomes.
R&D
Preclinical
Clinical
Commercial
JointRep®
JL-001
DR-001
Our medical device journey started with JointRep®, find out more!
